Edeset Uses

How do you administer this medicine?
sponsored

What is Edeset?

Edeset blocks the actions of chemicals in the body that can trigger nausea and vomiting.

Edeset is used to prevent nausea and vomiting that may be caused by surgery or by medicine to treat cancer (chemotherapy or radiation).

Edeset is not for preventing nausea or vomiting that is caused by factors other than cancer treatment or surgery.

Edeset may be used for purposes not listed in this medication guide.

Edeset indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Prevention of Nausea and Vomiting Associated with Highly Emetogenic Cancer Chemotherapy

Edeset (Edeset) oral soluble film is indicated for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2.

Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy

Edeset is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Prevention of Nausea and Vomiting Associated with Radiotherapy

Edeset is indicated for the prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.

Prevention of Postoperative Nausea and/or Vomiting

Edeset is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, Edeset is recommended even where the incidence of postoperative nausea and/or vomiting is low.

How should I use Edeset?

Use Edeset soluble film as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Edeset soluble film.

Uses of Edeset in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Edeset is used for preventing nausea and vomiting that may be caused by surgery or by medicine to treat cancer (chemotherapy or radiation).

Edeset description

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]

Edeset dosage

Edeset Dosage

Generic name: Edeset 4mg in 5mL

Dosage form: tablets, orally disintegrating tablets, oral solution

See also:

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Instructions for Use/Handling Edeset ODT

Orally Disintegrating Tablets:

Do not attempt to push Edeset ODT Tablets through the foil backing. With dry hands, PEEL BACK the foil backing of 1 blister and GENTLY remove the tablet. IMMEDIATELY place the Edeset ODT Tablet on top of the tongue where it will dissolve in seconds, then swallow with saliva. Administration with liquid is not necessary.

Prevention of Nausea and Vomiting Associated with Highly Emetogenic Cancer Chemotherapy:

The recommended adult oral dosage of Edeset is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin ≥50 mg/m2. Multiday, single-dose administration of a 24-mg dosage has not been studied.

Pediatric Use:

There is no experience with the use of a 24-mg dosage in pediatric patients.

Geriatric Use:

The dosage recommendation is the same as for the general population.

Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy:

The recommended adult oral dosage is one 8-mg Edeset Tablet or one 8-mg Edeset ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of Edeset) of Edeset

Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Edeset Tablet or one 8-mg Edeset ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of Edeset) of Edeset

Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.

Pediatric Use:

For pediatric patients aged 12 years and older, the dosage is the same as for adults. For pediatric patients aged 4 through 11 years, the dosage is one 4-mg Edeset Tablet or one 4-mg Edeset ODT Tablet or 5 mL (1 teaspoonful equivalent to 4 mg of Edeset) of Edeset

Oral Solution given 3 times a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. One 4-mg Edeset Tablet or one 4-mg Edeset ODT Tablet or 5 mL (1 teaspoonful equivalent to 4 mg of Edeset) of Edeset

Oral Solution should be administered 3 times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.

Geriatric Use:

The dosage is the same as for the general population.

Prevention of Nausea and Vomiting Associated with Radiotherapy, Either Total Body Irradiation, or Single High-dose Fraction or Daily Fractions to the Abdomen:

The recommended oral dosage is one 8-mg Edeset Tablet or one 8-mg Edeset ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of Edeset) of Edeset

Oral Solution given 3 times a day.

For total body irradiation, one 8-mg Edeset Tablet or one 8-mg Edeset ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of Edeset) of Edeset

Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.

For single high-dose fraction radiotherapy to the abdomen, one 8-mg Edeset Tablet or one 8-mg Edeset ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of Edeset) of Edeset

Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.

For daily fractionated radiotherapy to the abdomen, one 8-mg Edeset Tablet or one 8-mg Edeset ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of Edeset) of Edeset

Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.

Pediatric Use:

There is no experience with the use of Edeset Tablets, Edeset ODT Tablets, or Edeset

Oral Solution in the prevention of radiation-induced nausea and vomiting in pediatric patients.

Geriatric Use:

The dosage recommendation is the same as for the general population.

Postoperative Nausea and Vomiting:

The recommended dosage is 16 mg given as two 8-mg Edeset Tablets or two 8-mg Edeset ODT Tablets or 20 mL (4 teaspoonfuls equivalent to 16 mg of Edeset) of Edeset

Oral Solution 1 hour before induction of anesthesia.

Pediatric Use:

There is no experience with the use of Edeset Tablets, Edeset ODT Tablets, or Edeset

Oral Solution in the prevention of postoperative nausea and vomiting in pediatric patients.

Geriatric Use:

The dosage is the same as for the general population.

Dosage Adjustment for Patients with Impaired Renal Function:

The dosage recommendation is the same as for the general population. There is no experience beyond first-day administration of Edeset.

Dosage Adjustment for Patients with Impaired Hepatic Function:

In patients with severe hepatic impairment (Child-Pugh2 score of 10 or greater), clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life. In such patients, a total daily dose of 8 mg should not be exceeded.

More about Edeset (Edeset)

Consumer resources

Professional resources

Other formulations

Related treatment guides

Edeset interactions

See also:
What other drugs will affect Edeset?

sponsored

Drugs Affecting Cytochrome P-450 Enzymes

Edeset does not appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Edeset is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of Edeset. On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.

Apomorphine

Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with Edeset, the concomitant use of apomorphine with Edeset is contraindicated.

Phenytoin, Carbamazepine, And Rifampin

In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of Edeset was significantly increased and Edeset blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for Edeset is recommended for patients on these drugs.

Tramadol

Although there are no data on pharmacokinetic drug interactions between Edeset and tramadol, data from two small trials indicate that concomitant use of Edeset may result in reduced analgesic activity of tramadol. Patients on concomitant Edeset self administered tramadol more frequently in these trials, leading to an increased cumulative dose in patient-controlled administration (PCA) of tramadol.

Serotonergic Drugs

Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs).

Chemotherapy

In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of Edeset.

In a crossover trial in 76 pediatric patients, intravenous Edeset did not increase blood levels of high-dose methotrexate.

Temazepam

The coadministration of Edeset had no effect on the pharmacokinetics and pharmacodynamics of temazepam.

Alfentanil And Atracurium

Edeset does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. Interactions with general or local anesthetics have not been studied.

Drug Abuse And Dependence

Animal studies have shown that Edeset is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.

Edeset side effects

See also:
What are the possible side effects of Edeset?

sponsored

The following have been reported as adverse events in clinical trials of patients treated with Edeset, the active ingredient of Edeset. A causal relationship to therapy with Edeset has been unclear in many cases.

Chemotherapy-Induced Nausea and Vomiting

The adverse events in Table 5 have been reported in ≥ 5% of adult patients receiving a single 24-mg Edeset Tablet in 2 trials. These patients were receiving concurrent highly emetogenic cisplatin-based chemotherapy regimens (cisplatin dose ≥ 50 mg/m ).

Table 5: Principal Adverse Events in US Trials: Single Day Therapy With 24-mg Edeset Tablets (Highly Emetogenic Chemotherapy)

Event Edeset 24 mg q.d.

n = 300

Edeset 8 mg b.i.d.

n = 124

Edeset 32 mg q.d.

n = 117

Headache 33 (11%) 16 (13%) 17 (15%)
Diarrhea 13 (4%) 9 (7%) 3 (3%)

The adverse events in Table 6 have been reported in ≥ 5% of adults receiving either 8 mg of Edeset Tablets 2 or 3 times a day for 3 days or placebo in 4 trials. These patients were receiving concurrent moderately emetogenic chemotherapy, primarily cyclophosphamide-based regimens.

Table 6: Principal Adverse Events in US Trials: 3 Days of Therapy With 8-mg Edeset Tablets (Moderately Emetogenic Chemotherapy)

Event Edeset 8 mg b.i.d.

n = 242

Edeset 8 mg t.i.d.

n = 415

Placebo

n = 262

Headache 58 (24%) 113 (27%) 34 (13%)
Malaise/fatigue 32 (13%) 37 (9%) 6 (2%)
Constipation 22 (9%) 26 (6%) 1 ( < 1%)
Diarrhea 15 (6%) 16 (4%) 10 (4%)
Dizziness 13 (5%) 18 (4%) 12 (5%)

Central Nervous System: There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving Edeset.

Hepatic: In 723 patients receiving cyclophosphamide-based chemotherapy in US clinical trials, AST and/or ALT values have been reported to exceed twice the upper limit of normal in approximately 1% to 2% of patients receiving Edeset Tablets. The increases were transient and did not appear to be related to dose or duration of therapy. On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic hepatic disease did not occur. The role of cancer chemotherapy in these biochemical changes cannot be clearly determined.

There have been reports of liver failure and death in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology of the liver failure is unclear.

Integumentary: Rash has occurred in approximately 1% of patients receiving Edeset.

Other: Rare cases of anaphylaxis, bronchospasm, tachycardia, angina (chest pain), hypokalemia, electrocardiographic alterations, vascular occlusive events, and grand mal seizures have been reported. Except for bronchospasm and anaphylaxis, the relationship to Edeset was unclear.

Radiation-Induced Nausea and Vomiting

The adverse events reported in patients receiving Edeset Tablets and concurrent radiotherapy were similar to those reported in patients receiving Edeset Tablets and concurrent chemotherapy. The most frequently reported adverse events were headache, constipation, and diarrhea.

Postoperative Nausea and Vomiting

The adverse events in Table 7 have been reported in ≥ 5% of patients receiving Edeset Tablets at a dosage of 16 mg orally in clinical trials. With the exception of headache, rates of these events were not significantly different in the Edeset and placebo groups. These patients were receiving multiple concomitant perioperative and postoperative medications.

Table 7: Frequency of Adverse Events From Controlled Studies With Edeset Tablets (Postoperative Nausea and Vomiting)

Adverse Event Edeset 16 mg

(n = 550)

Placebo

(n = 531)

Wound problem 152 (28%) 162 (31%)
Drowsiness/sedation 112 (20%) 122 (23%)
Headache 49 (9%) 27 (5%)
Hypoxia 49 (9%) 35 (7%)
Pyrexia 45 (8%) 34 (6%)
Dizziness 36 (7%) 34 (6%)
Gynecological disorder 36 (7%) 33 (6%)
Anxiety/agitation 33 (6%) 29 (5%)
Bradycardia 32 (6%) 30 (6%)
Shiver(s) 28 (5%) 30 (6%)
Urinary retention 28 (5%) 18 (3%)
Hypotension 27 (5%) 32 (6%)
Pruritus 27 (5%) 20 (4%)

Preliminary observations in a small number of subjects suggest a higher incidence of headache when Edeset ODT

Orally Disintegrating Tablets are taken with water, when compared to without water.

Observed During Clinical Practice

In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of oral formulations of Edeset. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to Edeset.

Cardiovascular: Rarely and predominantly with intravenous Edeset, transient ECG changes including QT interval prolongation have been reported.

General: Flushing. Rare cases of hypersensitivity reactions, sometimes severe (e.g., anaphylaxis/anaphylactoid reactions, angioedema, bronchospasm, shortness of breath, hypotension, laryngeal edema, stridor) have also been reported. Laryngospasm, shock, and cardiopulmonary arrest have occurred during allergic reactions in patients receiving injectable Edeset.

Hepatobiliary: Liver enzyme abnormalities

Lower Respiratory: Hiccups

Neurology: Oculogyric crisis, appearing alone, as well as with other dystonic reactions

Skin: Urticaria, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

Special Senses: Eye Disorders: Cases of transient blindness, predominantly during intravenous administration, have been reported. These cases of transient blindness were reported to resolve within a few minutes up to 48 hours.

Drug Abuse And Dependence

Animal studies have shown that Edeset is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.

Edeset contraindications

See also:
What is the most important information I should know about Edeset?

You should not use this medication if you are allergic to Edeset or to similar medicines such as dolasetron (Anzemet), granisetron (Kytril), or palonosetron (Aloxi). Do not take Edeset if you are also using apomorphine (Apokyn).

Before taking Edeset, tell your doctor if you have liver disease, or a personal or family history of Long QT syndrome.

Edeset orally disintegrating tablets may contain phenylalanine. Tell your doctor if you have phenylketonuria (PKU).

The serious side effects of this medication include blurred vision or temporary vision loss (lasting from only a few minutes to several hours), slow heart rate, trouble breathing, anxiety, agitation, shivering, feeling like you might pass out, and urinating less than usual or not at all. Stop taking Edeset and call your doctor at once if you have any of these side effects.

Edeset may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Active ingredient matches for Edeset:

Ondansetron in India.

Ondansetron hydrochloride in India.


Unit description / dosage (Manufacturer)Price, USD
Edeset 2mg DPS / 30ml$ 0.46
EDESET oral drops 2 mg x 30ml (Edelweiss)$ 0.46

List of Edeset substitutes (brand and generic names):

EDEN 4MG TABLET 1 strip / 10 tablets each (Ethicare Pharma)$ 0.67
EDGON SYR syr 2 mg x 30ml (Indchemie)$ 0.55
EDGON-MD tab 4 mg x 10's (Indchemie)$ 0.84
2ml (Elfin)
Eldon Ondansetron INJ / 2ml (Elfin)
ELDON inj 4 mg x 2ml (Elfin)
Eldon Ondansetron INJ / 2ml (Elfin)
EMCHECK 12MG SYRUP 1 bottle / 30 ML syrup each (Apex Laboratories Pvt Ltd)$ 0.57
Emecule 4mg MD-TAB / 10$ 0.83
Emecule 2MG/5ml SYR / 30ml$ 0.56
Emefilm 4mg FILM / 1 (Delvin)$ 0.16
EMEFILM 2 MG TABLET 1 strip / 5 tablets each (Delvin)$ 0.71
EMEFILM 4MG SACHET 1 packet / 30 sachets each (Delvin)$ 5.24
EMEFILM 2 MG TABLET 1 strip / 30 tablets each (Delvin)$ 4.29
EMEFILM film 4 mg x 1's (Delvin)$ 0.16
Emefilm 2mg Tablet (Delvin)$ 0.14
Emefilm 4mg Sachet (Delvin)$ 0.17
Emefilm 4mg Tablet (Delvin)$ 0.15
EMEFILM-2 orally disintegrating tab 2 mg x 1's (Delvin)$ 0.14
4 mg x 10's (Molekule)$ 0.83
2 mg x 5 mL x 30ml (Molekule)$ 0.56
EMEKULE 2MG SYRUP 1 bottle / 30 ML syrup each (Molekule)$ 0.50
EMEKULE 4MG TABLET MD 1 strip / 10 tablet mds each (Molekule)$ 0.76
EMEKULE MD- tab 4 mg x 10's (Molekule)$ 0.83
EMEKULE syr 2 mg x 5 mL x 30ml (Molekule)$ 0.56
Emekule 2mg Syrup (Molekule)$ 0.50
Emekule 4mg Tablet MD (Molekule)$ 0.08
10 mg x 10's (Intas)$ 0.15
5 mg x 10ml (Intas)$ 0.20
5 mg x 2ml (Intas)$ 0.13
Emenorm 10mg TAB / 10 (Intas)$ 0.15
Emenorm 5mg INJ / 10ml (Intas)$ 0.20
Emenorm 5mg INJ / 2ml (Intas)$ 0.13
EMENORM 10MG TABLET 1 strip / 10 tablets each (Intas)$ 0.15
EMENORM 5MG INJECTION 1 vial / 10 ML injection each (Intas)$ 0.20
EMENORM 5MG INJECTION 1 vial / 2 ML injection each (Intas)$ 0.13
EMENORM 5MG TABLET 1 strip / 10 tablets each (Intas)$ 0.04
EMENORM tab 10 mg x 10's (Intas)$ 0.15
EMENORM inj 5 mg x 10ml (Intas)$ 0.22
EMENORM inj 5 mg x 2ml (Intas)$ 0.07
Emenorm 10mg TAB / 10 (Intas)$ 0.15
Emenorm 5mg INJ / 10ml (Intas)$ 0.20

References

  1. DailyMed. "ONDANSETRON: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "ondansetron". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "ondansetron". http://www.drugbank.ca/drugs/DB00904 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Edeset are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Edeset. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


1 consumer reported age

Users%
30-451
100.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved